Comparison Of The Incidence And Severity Of Peripheral Neuropathy Induced By Solvent-based Paclitaxel And Nab-paclitaxel

Objective: The purpose of this study is to use meta-analysis to evaluate the safety of nab-paclitaxel and solvent-based paclitaxel in the treatment of cancer patients,and to provide references for clinical rational drug use.Methods: We conducted a meta-analysis to compare the incidence and severity of peripheral neuropathy between nab-paclitaxel and solvent-based paclitaxel monotherapy.Results: The study included 18 studies and a total of 22 sets of data were obtained.The meta results show that nab-paclitaxel group had a higher incidence of peripheral neuropathy than solvent paclitaxel group.According to the subgroup analysis,the dose had a great influence on the incidence and severity of peripheral neuropathy in two groups.The incidence of nab-paclitaxel’s peripheral neuropathy in the low-dose groups and the high-dose groups was higher than that of solvent-based paclitaxel,and there was a statistical difference.And when we applied the same method of evaluating peripheral neuropathy(NCI-CTC),the differences in the incidence of peripheral neuropathy became more significant.Moreover,the incidence of high-grade peripheral neuropathy induced by nab-paclitaxel was significantly higher than that induced by solvent-based paclitaxel.Conclusions:1.Among cancer patients accepting single-agent chemotherapy,the incidence of peripheral neuropathy caused by nab-paclitaxel was higher than that caused by solvent-based paclitaxel.The incidence of high-grade peripheral neuropathy was significantly higher in solvent-based paclitaxel group.It reminds us that compared with solvent-based paclitaxel,nab-paclitaxel has a higher incidence of peripheral neuropathy and is more likely to cause high-grade peripheral neuropathy.We should pay more attention to the occurrence of peripheral neuropathy when using nab-paclitaxel.2.Among cancer patients undergoing single-agent chemotherapy,the incidence of peripheral neuropathy in nab-paclitaxel was higher than that of solvent-based paclitaxel in different dose groups.Therefore,when using paclitaxel for treatment,we may be more inclined to using solvent-based paclitaxel rather than nab-paclitaxel,which provides us with a certain basis for clinical drug selection.